MIRA INFORM REPORT

Report No. :	498189
Report Date :	19.03.2018

IDENTIFICATION DETAILS

Name :	INTAS PHARMACEUTICALS LIMITED (w.e.f. 30.03.1995)
Formerly Known As :	INTAS LABORATORIES LIMITED (w.e.f. 29.03.1995) INTAS LABORATORIES PRIVATE LIMITED
Registered Office :	Corporate House, Near Sola Bridge, S. G. Highway, Thaltej, Ahmedabad – 380054, Gujarat
Tel. No.:	91-79-66523100/ 26576655
Country :	India
Financials (as on) :	31.03.2016
Date of Incorporation :	31.05.1985
Com. Reg. No.:	04-007866
Capital Investment / Paid-up Capital :	INR 1147.440 Million
CIN No.: [Company Identification No.]	U24231GJ1985PLC007866
IEC No.: [Import-Export Code No.]	0896004341
GSTN : [Goods & Service Tax Registration No.]	24AAACI5120L1ZU
TAN No.: [Tax Deduction & Collection Account No.]	Not Available
PAN No.: [Permanent Account No.]	AAACI5120L
Legal Form :	A Closely Held Public Limited Liability Company
Line of Business :	Manufacturing, Marketing, Distribution, Sale of Finished Pharmaceutical Formulations, Active Pharmaceutical Ingredient (API), Medical Appliances, Medical Devices. (Registered Activity and also confirmed by management)
No. of Employees :	12000 (approximately)

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23^rd January 2017)

MIRA’s Rating :

A+

Credit Rating	Explanation	Rating Comments
A+	Low Risk	Business dealings permissible with low risk of default

Maximum Credit Limit :	USD 150000000
Status :	Excellent
Payment Behaviour :	Regular
Litigation :	Clear
Comments :	Subject was incorporated in the year 1985 and it is a pharmaceutical manufacturing company based in Ahmedabad, Gujarat. It is an old and established company having excellent track record. As per 2016 financial record, the company has achieved revenue growth of 28% as compared to the previous year along with a decent profit margin of 19.10%. The sound financial profile of the company is marked by adequate net worth base along with comfortable leverage and liquidity position. The rating further derive strength from the vast experience of its promoters in the pharmaceutical industry, established marketing and distribution network, diversified product portfolio along with healthy growth prospect of Indian pharmaceutical industry. Business is active. Payments are reported to be regular and as per commitments. In view of strong financial and established position, the company can be considered for business dealings at usual trade terms and conditions. Note: As per Registrar of Companies, the date of balance sheet i.e. financials filed is shown as 31st March, 2017 but documents related to the financials for the year 2017 are not available.

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (30.09.2017)	Current Rating (31.12.2017)
India	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

EXTERNAL AGENCY RATING

Rating Agency Name	CARE
Rating	Long Term Borrowing = AA
Rating Explanation	High degree of safety and very low credit risk.
Date	09.06.2017

Rating Agency Name	CARE
Rating	Short Term Borrowing: A1+
Rating Explanation	Very strong degree of safety and carry lowest credit risk.
Date	09.06.2017

RBI DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2016.

BIFR (Board for Industrial & Financial Reconstruction) LISTING STATUS

Subject’s name is not listed as a Sick Unit in the publicly available BIFR (Board for Industrial & Financial Reconstruction) list as of 19.03..2018

IBBI (Insolvency and Bankruptcy Board of India) LISTING STATUS

Subject’s name is not listed in the publicly available IBBI (Insolvency and Bankruptcy Board of India) list as of report date.

INFORMATION PARTED BY (GENERAL DETAILS)

Name :	Mr. Prithvi
Designation :	Treasury Manager
Contact No.:	91-79-66523100

LOCATIONS

Registered Office :	Corporate House, Near Sola Bridge, S. G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, India
Tel. No.:	91-79-66523100/ 26576655
Fax No.:	91-79-26578862
E-Mail :	manoj_nair@intaspharma.com
Website :	www.intaspharma.com
Corporate Office :	2^nd Floor, Chinubhai Centre, Ashram Road, Ahmedabad - 380009, Gujarat, India
Factory 1 :	Plot No.: 423, P/A, GIDC, Moraiya, Sarkhej Bawala Road, Ral – Sanand, Moraiya, Ahmedabad - 382213, Gujarat, India
Factory 2 :	7/3, GIDC Estate, Behind Dena Bank, Vatva, Ahmedabad – 382445, Gujarat, India
Tel. No.:	91-79-25830207/25831279
Factory 3 :	Camp Road, Selaqui, Dehradun – 248001, Uttrakhand, India
Tel. No.:	91-135-2698659/2699098/2699174/2699175
Fax No.:	91-135-2699099
Factory 4 :	Survey No. 44-B, Naldhari Village, Valia Taluka - 393135. District Bharuch, Gujarat, India.
Tel. No.:	91-2643-270015/270389
Factory 5 :	Plot No. 457-458, Sarkhej Bavla Highway, Matoda Village, Sanand Taluka, Ahmedabad – 382210, Gujarat, India
Tel. No.:	91-2717-661298
Fax No.:	91-2717-661106
Factory 6 :	Plot No. 5, 6, 7, Pharmez, Sarkhej-Bavla Highway, Matoda Village, Sanand Taluka, Ahmedabad - 382 210, Gujarat, India
Tel. No.:	91-2717-619100
Fax No.:	91-2717-619999
Factory 7 :	Near IOC Depo, N.H. No. 31A, Bhagey Khola, Majhitar, Rangpo – 737132, East Sikkim, India
Tel. No.:	91-3592-246417/18/32
Fax No.:	91-3592-246417
Factory 7 :	85-87, Kailash Industrial Estate, Iyava Village, Sanand Taluka, Ahmedabad – 382210, Gujarat, India
Tel. No.:	91-2717-284188/89/90

DIRECTORS

AS ON 31.03.2017

Name :

Mr. Urmish Hasmukh Chudgar

Designation :

Managing Director

Address :

16, Nishant Bunglows Part-1, Behind Shyamal Row House Satellite Road, Ahmedabad - 380015, Gujarat, India

Date of Birth/Age :

16.02.1959

Qualification :

MD in Oncology and Haemetoly

Date of Appointment :

30.09.1996

PAN No.:

ABHPC1733G

DIN No.:

00096080

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U24229GJ1998PTC035149	PRIME PAEDIATRICS PRIVATE LIMITED	16/12/1998	-
U24231GJ2000PLC037582	INTAS PHARMA LIMITED.	21/03/2000	-
U24240GJ2000PLC037850	CELESTIAL BIOLOGICALS LIMITED	25/04/2000	-
U73100GJ2000PLC038979	INDUS BIOTHERAPEUTICS LIMITED	01/11/2007	-
U24231GJ2001PLC039545	ASTRON RESEARCH LIMITED	15/05/2001	-
U21029GJ2001PLC039733	ASTRON PACKAGING LIMITED	03/07/2001	-
U24231GJ2003PLC041866	ACCORD HEALTHCARE LIMITED	01/02/2003	-
U19129GJ1997NPL032264	ADVANCED TRANSFUSION MEDICINE RESEARCH FOUNDATION	06/05/1997	-
U73100GJ2003PLC042948	CYTAS RESEARCH LIMITED	22/09/2003	-
U24230GJ2005PLC047111	INTAS BIOPHARMACEUTICALS LIMITED	29/11/2007	-
U73100GJ2008PLC054736	ONCOLOGY SERVICES INDIA LIMITED	11/08/2008	-
U85195GJ2009PLC057059	UNIPATH SPECIALTY LABORATORY LIMITED	26/05/2009	-
U33110GJ2010PLC061475	INTAS MEDI DEVICES LIMITED	07/07/2010	-

Name :

Mr. Binish Hasmukh Chudgar

Designation :

Managing Director

Address :

11, Akashneem Bunglows, Vastrapur, Ahmedabad-380001, Gujarat, India

Date of Birth/Age :

01.12.1963

Qualification :

B Com, MBA

Date of Appointment :

31.05.1985

PAN No.:

ABDPC6876C

DIN No.:

00119503

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U51909GJ1955PTC000577	EQUATORIAL PRIVATE LIMITED	01/08/1994	-
U65910GJ1994PTC023392	INTAS ENTERPRISE PRIVATE LIMITED	24/10/1994	-
U51100GJ1994PTC023865	EPSILON MARKETING AND CONSULTANCY PRIVATE LIMITED	16/10/2000	-
U24236GJ1998PLC034883	LAMBDA THERAPEUTIC RESEARCH LIMITED	27/10/1998	-
U24229GJ1998PTC035149	PRIME PAEDIATRICS PRIVATE LIMITED	16/12/1998	-
U24231GJ2000PLC037582	INTAS PHARMA LIMITED.	02/12/2002	-
U73100GJ2000PLC038979	INDUS BIOTHERAPEUTICS LIMITED	27/11/2000	-
U24231GJ2001PLC039545	ASTRON RESEARCH LIMITED	15/05/2001	-
U21029GJ2001PLC039733	ASTRON PACKAGING LIMITED	03/07/2001	-
U24231GJ1973PLC040442	ANDRE LABORATORIES LIMITED	15/10/2004	-
U24231GJ2003PLC041866	ACCORD HEALTHCARE LIMITED	20/01/2003	-
U24230GJ2005PLC047111	INTAS BIOPHARMACEUTICALS LIMITED	30/09/2010	-
U24233GJ2007PLC050155	JINA PHARMACEUTICALS LIMITED.	06/03/2007	-
U33110GJ2010PLC061475	INTAS MEDI DEVICES LIMITED	06/09/2012	-
U33110GJ2013PTC073537	ALVI-INTAS MEDICAL DEVICES PRIVATE LIMITED	12/02/2013	-
U63040GJ2015PTC084805	ASTRON TOURS AND TRAVELS PRIVATE LIMITED	16/08/2016	-

Name :

Mr. Hasmukh Chudgar

Designation :

Whole-time Director

Address :

13-14, Sanidhya Bunglows, Near Someshwar Complex, Shyamal Cross Road, Satellite, Ahmedabad-380053, Gujarat, India

Date of Birth/Age :

16.05.1933

Qualification :

B Pharm

Date of Appointment :

31.05.1985

PAN No.:

AARPC4022H

DIN No.:

00172265

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U51909GJ1955PTC000577	EQUATORIAL PRIVATE LIMITED	30/09/2014	-
U65910GJ1994PTC023392	INTAS ENTERPRISE PRIVATE LIMITED	30/09/2014	-
U24231GJ2000PLC037582	INTAS PHARMA LIMITED.	29/09/2007	-
U73100GJ2000PLC038979	INDUS BIOTHERAPEUTICS LIMITED	01/06/2002	-
U24231GJ1973PLC040442	ANDRE LABORATORIES LIMITED	24/02/2001	-
U24230GJ2005PLC047111	INTAS BIOPHARMACEUTICALS LIMITED	16/01/2006	-
U33110GJ2010PLC061475	INTAS MEDI DEVICES LIMITED	07/07/2010	-
U24230GJ2015PTC083143	INTAS LIFESCIENCES PRIVATE LIMITED	07/05/2015	-

Name :

Mr. Nimish Hasmukh Bhai Chudgar

Designation :

Managing Director

Address :

13-14, Sanidhya Bunglows, Near Someshwar Complex, Shyamal Cross Road, Satellite, Ahmedabad-380053, Gujarat, India

Date of Birth/Age :

19.08.1960

Qualification :

B. SC

Date of Appointment :

31.05.1985

PAN No.:

ABDPC6875B

DIN No.:

00212400

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U24230GJ2015PTC083143	INTAS LIFESCIENCES PRIVATE LIMITED	07/05/2015	-
U33110GJ2013PTC073537	ALVI-INTAS MEDICAL DEVICES PRIVATE LIMITED	12/02/2013	-
U85110GJ2014PTC080551	OCCURA EYECARE PRIVATE LIMITED	22/08/2014	-
U52202GJ2012PTC072362	ARRON FRESH PRIVATE LIMITED	18/10/2012	-
U33110GJ2010PLC061475	INTAS MEDI DEVICES LIMITED	07/07/2010	-
U73100GJ2008PLC054736	ONCOLOGY SERVICES INDIA LIMITED	21/08/2012	-
U24230GJ2005PLC047111	INTAS BIOPHARMACEUTICALS LIMITED	16/01/2006	-
U73100GJ2003PLC042948	CYTAS RESEARCH LIMITED	21/08/2012	-
U19129GJ1997NPL032264	ADVANCED TRANSFUSION MEDICINE RESEARCH FOUNDATION	06/05/1997	-
U24231GJ2003PLC041866	ACCORD HEALTHCARE LIMITED	20/01/2003	-
U24231GJ1973PLC040442	ANDRE LABORATORIES LIMITED	24/02/2001	-
U21029GJ2001PLC039733	ASTRON PACKAGING LIMITED	03/07/2001	-
U24231GJ2001PLC039545	ASTRON RESEARCH LIMITED	15/05/2001	-
U73100GJ2000PLC038979	INDUS BIOTHERAPEUTICS LIMITED	27/11/2000	-
U24240GJ2000PLC037850	CELESTIAL BIOLOGICALS LIMITED	21/08/2012	-
U24231GJ2000PLC037582	INTAS PHARMA LIMITED.	01/04/2011	-
U24229GJ1998PTC035149	PRIME PAEDIATRICS PRIVATE LIMITED	16/12/1998	-
U65910GJ1994PTC023392	INTAS ENTERPRISE PRIVATE LIMITED	24/10/1994	-
U51909GJ1955PTC000577	EQUATORIAL PRIVATE LIMITED	01/08/1994	-

Name :

Ms. Kusumben Hasmukhbhai Chudgar

Designation :

Director

Address :

13-14, Sanidhya Bunglows, Near Someshwar Complex, Shyamal Cross Road, Satellite, Ahmedabad-380053, Gujarat, India

Date of Appointment :

01.04.2015

DIN No.:

00279041

Name :

Mr. Nitin Ram Potdar

Designation :

Director

Address :

402/A-2, 4th Floor, Sumer Trinity Tower 2, TPS-4, 1052, New Prabhadevi Road, Prabhadevi, Mumbai-400025, Maharashtra, India

Date of Appointment :

09.02.2011

DIN No.:

00452644

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U24244MH1980PTC023362	KEVA FRAGRANCES PRIVATE LIMITED	27/03/2015	-
U24110MH1978PTC020545	KEVA FRAGRANCES PRIVATE LIMITED	01/12/2016	-
L74999MH1955PLC009593	S H KELKAR AND COMPANY LIMITED	18/09/2014	-
U80301MH2016PTC283907	MAXPLORE SCHOOL OF BUSINESS PRIVATE LIMITED	20/07/2016	-

Name :

Mr. Surender Kumar Tuteja

Designation :

Director

Address :

S-307, 2nd Floor, Panchsheel Park, New Delhi-110017, India

Date of Appointment :

09.02.2011

DIN No.:

00594076

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U74900DL2015PTC279379	RED CARPET RETAIL PRIVATE LIMITED	22/04/2015	-
U15209DL2005PLC135838	DAAWAT FOODS LIMITED	30/09/2011	-
L50101PB1983PLC005516	SML ISUZU LIMITED	20/06/1998	-
U74140DL2006PTC146410	TFS BUSINESS ADVISORS INDIA PRIVATE LIMITED	30/09/2016	-
U65999MH2004PTC144113	PEGASUS ASSETS RECONSTRUCTION PRIVATE LIMITED	03/09/2007	-
U70109CH2014PTC035147	RED CARPET LIVING PRIVATE LIMITED	28/07/2014	-
U40108MH2007PTC167396	TOPWORTH ENERGY PRIVATE LIMITED	30/09/2010	-
U74999DL2010PLC205776	QRG MEDICARE LIMITED	12/07/2016	-
L31900DL1983PLC016304	HAVELLS INDIA LIMITED	29/09/2010	-
U17290PB2010PLC033582	TRIDENT CORPORATION LIMITED	29/09/2012	-
U74210CH1998PTC022084	NORWEST ESTATES PRIVATE LIMITED	29/04/2013	-
U63090GJ2005PLC045356	ADANI AGRI LOGISTICS LIMITED	08/08/2016	-
U74120DL2008PTC180485	DEVENIO OPTIMUS ADVISORS PRIVATE LIMITED	02/08/2011	-
U40102KA2008PLC045442	SHREE RENUKA ENERGY LIMITED	29/09/2011	-
U01100MH1987PTC042508	T BHIMJYANI WAREHOUSING COLD CHAIN PRIVATE LIMITED	06/08/2004	-
U63090GJ2005PLC046510	ADANI LOGISTICS LIMITED	11/08/2008	-
L01542KA1995PLC019046	SHREE RENUKA SUGARS LIMITED	05/01/2008	-
L74999HR2002PLC034805	A2Z INFRA ENGINEERING LIMITED	30/09/2008	-

Name :

Mr. Tilokchand Punamchand Ostwal

Designation :

Director

Address :

103 Falcon's Crest, G.D. Ambekar Marg, Parel, Mumbai-400012, Maharashtra, India

Date of Appointment :

19.03.2011

DIN No.:

00821268

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U45202MH1993PLC074836	OBEROI CONSTRUCTIONS LIMITED	04/05/2010	-
L45200MH1998PLC114818	OBEROI REALTY LIMITED	30/09/2008	-
U29309MH1987PLC257475	WTI ADVANCED TECHNOLOGY LIMITED	30/09/2000	-
U65999MH2006PTC164773	JPMORGAN ASSET MANAGEMENT INDIA PRIVATE LIMITED	28/09/2017	-
U74120MH2012PTC235204	P & O ADVISORS PRIVATE LIMITED	31/08/2012	-
U45400MH2014PTC255010	INCLINE REALTY PRIVATE LIMITED	01/07/2015	-

Name :

Mr. Hemant Devidas Sheth

Designation :

Director

Address :

201, Angan Building, Plot No. 40, T. V. Chidambaram Marg, Sion (East), Mumbai – 400022, Maharashtra, India  

Date of Appointment :

09.02.2011

DIN No.:

01261486

Name :

Mr. Sanjiv Dwarkanath Kaul

Designation :

Nominee Director

Address :

22, Siris Road, DLF Qutab Enclave, Phase-3, Gurugram - 122002, Haryana, India

Date of Appointment :

16.06.2012

DIN No.:

01550413

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U36910MH1954PTC009449	BIERI PRIVATE LIMITED	06/01/2013	-
U21098MH2007PTC170239	DIVINE PAPER PRODUCTS PRIVATE LIMITED	24/04/2007	-
U74999MH2016PTC280997	SPIRITUAL ESSENTIALS PRIVATE LIMITED	12/05/2016	-

Name :

Mr. John Geoffrey Goddard

Designation :

Director

Address :

38 Delvino Road, Fulham, London, Sw64aj, United Kingdom

Date of Appointment :

09.02.2011

DIN No.:

03420601

Name :

Mr. Venkatesh Ratnasami

Designation :

Nominee Director

Address :

Old No- 12, New No 25 C-1, Shanmuga Villa, Venkartaman Street, T Nagar, Chennai – 600017, Tamilnadu, India

Date of Appointment :

13.11.2014

DIN No.:

03433678

Other Directorship:

CIN/FCRN	Company Name	Begin Date	End Date
U85110KA2010PTC052540	MANIPAL HEALTH ENTERPRISES PRIVATE LIMITED	11/10/2017	-
U67190MH2000PTC154942	TEMASEK HOLDINGS ADVISORS INDIA PRIVATE LIMITED	15/09/2011	-

KEY EXECUTIVES

Name :	Mr. Jayesh Shantilal Shah
Designation :	Chief Executive Officer
Address :	15, Nirgun Bungalows,Nr. Ambrakadamb Super Society Ramdev Nagar Char Rasta Ahmedabad – 380015, Gujarat, India
Date of Birth/Age :	11.02.1964
Date of Appointment :	12.03.2015
PAN No.:	ACSPS6242G
Name :	Mr. Manoj Narayanan Nair
Designation :	Company Secretary
Address :	"Laxmi Nivas" 648/1 Sector-4 C, Gandhinagar Gandhinagar – 382006, Gujarat, India
Date of Birth/Age :	20.10.1979
Date of Appointment :	08.06.2007
PAN No.:	AEBPN7909Q
Name :	Mr. Prithvi
Designation :	Treasury Manager

MAJOR SHAREHOLDERS

AS ON 31.03.2017

Names of Shareholders	No. of Shares
Hasmukh Kesarichand Chudgar	213145
Hasmukh Kesarichand Chudgar	3422804
Kusumben Hasmukh Chudgar	2367503
Kusumben Hasmukh Chudgar	38462
Binish Hasmukh Chudgar	5945735
Binish Hasmukh Chudgar	301874
Bindiben Binish Chudgar	6944851
Nimish Hasmukh Chudgar	6164115
Nimish Hasmukh Chudgar	313054
Binaben Nimish Chudgar	5483291
Urmish Hasmukh Chudgar	151995
Parul Urmish Chudgar	7032831
Shail Urmish Chudgar	4563868
Shail Urmish Chudgar	233099
Intas Enterprise Private Limited	4106667
Equatorial Private Limited	47432000
Cytas Research Limited	1509131
Dunearn Investments Pte Limited	11621100
CARAVAGGIO	6898447
Total	114743972

AS ON 29.09.2017

Equity Share Break up	Percentage
Category
Promoters – [Individual/Hindu Undivided Family – Indian]	37.63
Promoters – [Bodies corporate]	46.23
Public/Other than promoters -[Bodies corporate]	16.09
Public/Other than promoters – (Other -Trust)	0.05
Total	100.00

BUSINESS DETAILS

Line of Business :

Manufacturing, Marketing, Distribution, Sale of Finished Pharmaceutical Formulations, Active Pharmaceutical Ingredient (API), Medical Appliances, Medical Devices. (Registered Activity and also confirmed by management)

Products :

NIC Code No.	Product/Services Description
210	Manufacturing, Marketing, Distribution, Sale of finished Pharmaceutical Formulations, Active Pharmaceutical Ingredient (API), Medical Appliances, Medical Devices.

ITC Code No.	Product Description
30049049	Capecitabine
30049049	Mitomycin
30049049	Bortezomib

Brand Names :

Not Available

Agencies Held :

Not Divulged

Exports :

Product :

• Finished Goods

Countries :

• United States of America
• Europe

Imports :

Product :

• Raw Material

Countries :

• Europe
• China

Terms :

Selling :

L/C, Cheque, Bank Transfer and RTGS

Purchasing :

L/C, Cheque, Bank Transfer and RTGS

PRODUCTION STATUS – (NOT AVAILABLE)

GENERAL INFORMATION

Suppliers :

Reference :	Not Divulged
Name of the Person :	--
Contact No.:	--
Since How Long Known :	--
Maximum Limit Dealt :	--
Experience :	--
Remark :	--

Customers :

Reference :	Not Divulged
Name of the Person :	--
Contact No.:	--
Since How Long Known :	--
Maximum Limit Dealt :	--
Experience :	--
Remark :	--

No. of Employees :

12000 (approximately)

Bankers :

Bank Name	Standard Chartered Bank
Branch	Marina Bay Financial Centre Tower 1, Level 23, 8 Marina Boulevard – 018981, Singapore
Person Name (With Designation)	--
Contact Number	--
Name of Account Holder	--
Account Number	--
Account Since (Date/Year of Account Opening)	--
Average Balance Maintained (If Possible)	--
Credit Facilities Enjoyed (If any)	--
Account Operation	--
Remarks (If any)	--

Facilities :

Secured Loan	31.03.2016 (INR in Million)	31.03.2015 (INR in Million)
Long-term Borrowings
Other loans and advances	138.074	127.800
Short-term borrowings
Term loans from banks	3431.596	2980.991
Total	3569.670	3108.791

Auditors :
Name :	Apaji Amin and Company LLP Chartered Accountants
Address :	304, Akansha Building, Opposite Vadilal House, Navrangpura, Ahmedabad – 380009, Gujarat, India
PAN No.:	AAFFA6140C
Memberships :	Not Available
Collaborators :	Not Available
Subsidiaries (As on 29.09.2017) :	· Accord Farma SA DE CV, Mexico · Accord Farmaceutica Ltda., Brazil · Accord Healthcare Inc., North Carolina, Usa · Accord Healthcare (Pty) Limited, South Africa · Accord Healthcare Inc., Canada · Accord Healthcare NZ Limited, New Zealand · Accord Healthcare Limited, United Kingdom · Accord Healthcare Sac, Peru · Intas Medi Devices Limited, India [CIN No.U33110GJ2010PLC061475] · Andre Laboratories Limited, India [CIN No.U24231GJ1973PLC040442] · Astron Research Limited, United Kingdom · Accord Healthcare Limited [CIN No. U24231GJ2003PLC041866] · Accord Healthcare Pty. Limited, Australia · Accord Healthcare SAS, France · Accord Healthcare BV, Netherlands · Accord Healthcare Italia SRL, Italy · Accord Healthcare Sociedad Limitada Spain · Accord Healthcare Polska Spolka Z Organiczona Odpowiedzialnoscia, Poland · Accord Healthcare AB, Sweden · Accord Healthcare BVPA, Belgium · Farmabiot SA DE CV, Mexico · Accord Healthcare OY, Finland · Accord Healthcare GmbH, Austria · Accord Healtcare Ireland Limited, Ireland · Accord Healthcare SDN. BHD., Malay · Accord Healthcare MENA DMCC, UAE · Accord Biopharma Inc., USA · Accord Healthcare HK Limited, Hong Kong · Accord Healthcare s.r.o, Czech Republic · Accord Healthcare Private Limited, Singapore · Accord Healthcare Pharmaceutical LLC, Slovania · Accord Healthcare SRL, Romania · Accord Healtcare Unipessoal Lda., Portugal · Genim s.r.o., Czech Republic · Accord Healthcare GmbH, Germany · Accord Healthcare OU, Estonia · Accord Healthcare Limited, (Malta)
Associate :	· Alvi Intas Medical Devices Private Limited [CIN No.U33110GJ23013PTC073537]
Fellow Subsidiary Company (As on 2016) :	· Accord Healthcare Pty. Limited, Australia · Farmabiot SA DE CV Mexico, Mexico
Joint Venture (As on 2016) :	· Alvi-Intas Medical Devices Private Limited
Enterprises which are owned, or have significant influence of or are partners with Key management personnel and their relatives (as on 2016) :	· One Advertising and Communication Services Limited, |India · Lambda Therapeutic Research Limited, India · Lambda Therapeutic Research Inc., Canada · Unipath Specialty Laboratory Limited, India · Astron Packaging Limited, India · Astron Tours and Travels Private Limited, India · Equatorial Private Limited, India · Intas Enterprise Private Limited, India · Intas Welfare Trust, India · Cytas Research Limited, India

CAPITAL STRUCTURE

AS ON 29.09.2017

Authorised Capital :

No. of Shares	Type	Value	Amount
173916752	Equity Shares	INR 10/- each	INR 1739.167 Million

Issued, Subscribed & Paid-up Capital :

No. of Shares	Type	Value	Amount
114743972	Equity Shares	INR 10/- each	INR 1147.440 Million

FINANCIAL DATA

[all figures are INR Million]

ABRIDGED BALANCE SHEET

SOURCES OF FUNDS	31.03.2016	31.03.2015	31.03.2014
I.              EQUITY AND LIABILITIES
(1)Shareholders' Funds
(a) Share Capital	1147.440	1147.440	1144.363
(b) Reserves & Surplus	51009.412	40836.329	26890.146
(c) Money received against share warrants	0.000	0.000	0.000
(2) Share Application money pending allotment	0.000	0.000	0.000
Total Shareholders’ Funds	52156.852	41983.769	28034.509
(3) Non-Current Liabilities
(a) long-term borrowings	156.111	1057.117	1016.875
(b) Deferred tax liabilities (Net)	1564.964	1288.703	730.497
(c) Other long term liabilities	226.922	233.732	198.453
(d) long-term provisions	752.036	547.523	410.386
Total Non-current Liabilities	2700.033	3127.075	2356.211
(4) Current Liabilities
(a) Short term borrowings	4100.807	3850.283	4631.483
(b) Trade payables	10032.559	8934.639	6071.607
(c) Other current liabilities	517.618	395.759	768.476
(d) Short-term provisions	0.000	413.198	334.712
Total Current Liabilities	14650.984	13593.879	11806.278
TOTAL	69507.869	58704.723	42196.998
II.          ASSETS
(1) Non-current assets
(a) Fixed Assets
(i) Tangible assets	10010.407	8986.243	7908.565
(ii) Intangible Assets	9161.502	9910.730	1541.443
(iii) Capital work-in-progress	2645.119	1076.981	456.499
(iv) Intangible assets under development	1676.828	2959.705	2820.599
(b) Non-current Investments	5512.048	5434.045	5677.156
(c) Deferred tax assets (net)	0.000	0.000	0.000
(d) Long-term Loan and Advances	3647.243	3179.557	2493.294
(e) Other Non-current assets	4.299	4.852	6.307
Total Non-Current Assets	32657.446	31552.113	20903.863
(2) Current assets
(a) Current investments	0.000	0.000	0.000
(b) Inventories	11582.011	7371.431	6270.865
(c) Trade receivables	20639.278	16582.147	12896.168
(d) Cash and cash equivalents	215.352	226.765	287.400
(e) Short-term loans and advances	4413.782	2972.267	1838.702
(f) Other current assets	0.000	0.000	0.000
Total Current Assets	36850.423	27152.610	21293.135
TOTAL	69507.869	58704.723	42196.998

PROFIT & LOSS ACCOUNT

	PARTICULARS	31.03.2016	31.03.2015	31.03.2014
	SALES
	Income	56154.951	43867.844	40957.989
	Other Income	174.422	534.081	589.725
	TOTAL	56329.373	44401.925	41547.714
Less	EXPENSES
	Cost of Materials Consumed	17164.909	14812.585	10248.214
	Purchases of Stock-in-Trade	5466.117	3989.638	9466.730
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1977.348)	(11.414)	136.045
	Employees benefits expense	5678.979	4528.030	3421.821
	CSR Expenditure	1.248	1.751	0.000
	Exceptional Item	4.672	66.052	0.000
	Other expenses	13939.549	11541.787	9720.877
	TOTAL	40278.126	34928.429	32993.687
Less	PROFIT/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION	16051.247	9473.496	8554.027
Less	FINANCIAL EXPENSES	155.299	162.871	340.018
	PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION	15895.948	9310.625	8214.009
Less	DEPRECIATION/ AMORTISATION	2404.915	2254.040	973.075
	PROFIT/ (LOSS) BEFORE TAX	13491.033	7056.585	7240.934
Less	TAX	2765.538	1430.409	1168.411
	PROFIT/ (LOSS) AFTER TAX	10725.495	5626.176	6072.523
Add	PREVIOUS YEARS’ BALANCE BROUGHT FORWARD	40836.329	35210.153	29137.630
Less	APPROPRIATIONS
	Interim equity dividend	458.976	0.000	0.000
	Equity dividend tax	93.436	0.000	0.000
	Total	552.412	0.000	0.000
	Balance Carried to the B/S	51009.412	40836.329	35210.153
	EARNINGS IN FOREIGN CURRENCY	28779.607	19857.267	18569.039
	Earnings / (Loss) Per Share (INR)	93.47	54.97	55.02

Particulars	31.03.2017
Revenue from Operations	83842.000
Profit before Interest, Depreciation and Tax	17664.000
Profit After Tax	10313.000

The above information has been taken from indirect Source.

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

Particulars	31.03.2016	31.03.2015	31.03.2014
Current Maturities of Long term debt	40.767	26.400	543.726
Net cash flows from (used in) operations	7615.406	5677.220	5256.598
Net cash flows from (used in) operating activities	4582.329	3629.884	4006.942

KEY RATIOS

EFFICIENCY RATIOS

PARTICULARS	31.03.2016	31.03.2015	31.03.2014
Average Collection Days [Sundry Debtors / Income * 365]	134.15	137.97	114.93
Account Receivables Turnover [Income / Sunday Debtors]	2.72	2.65	3.18
Average Payment Days (Sundry Creditors / Purchases * 365 Days)	161.81	173.44	112.41
Inventory Turnover (Operating Income / Inventories)	1.39	1.29	1.36
Asset Turnover (Operating Income / Net Fixed Assets)	0.68	0.41	0.67

LEVERAGE RATIOS

PARTICULARS	31.03.2016	31.03.2015	31.03.2014
Debt Ratio ((Borrowing + Current Liabilities) / Total Assets)	0.21	0.25	0.32
Debt Equity Ratio (Total Liability / Networth)	0.08	0.12	0.22
Current Liabilities to Networth (Current Liabilities / Net Worth)	0.28	0.32	0.42
Fixed Assets to Networth (Net Fixed Assets / Networth)	0.45	0.55	0.45
Interest Coverage Ratio (PBIT / Financial Charges)	103.36	58.17	25.16

PROFITABILITY RATIOS

PARTICULARS		31.03.2016	31.03.2015	31.03.2014
PAT to Sales ((PAT / Sales) * 100)	%	19.10	12.83	14.83
Return on Total Assets ((PAT / Total Assets) * 100)	%	15.43	9.58	14.39
Return on Investment (ROI) ((PAT / Networth) * 100)	%	20.56	13.40	21.66

SOLVENCY RATIOS

PARTICULARS	31.03.2016	31.03.2015	31.03.2014
Current Ratio (Current Assets / Current Liabilities)	2.52	2.00	1.80
Quick Ratio ((Current Assets – Inventories) / Current Liabilities)	1.72	1.46	1.27
G-Score Ratio Financial (Networth / Total Assets)	0.75	0.72	0.66
G-Score Ratio Debt (Debts / Equity Capital)	3.75	4.30	5.41
G-Score Ratio Liquidity (Total Current Assets / Total Current Liabilities)	2.52	2.00	1.80

Total Liability = Short-term Debt + Long-term Debt + Current Maturities of Long-term debts

FINANCIAL ANALYSIS

[all figures are in INR Million]

DEBT EQUITY RATIO

Particular	31.03.2014	31.03.2015	31.03.2016
	(INR In Million)	(INR In Million)	(INR In Million)
Share Capital	1144.363	1147.440	1147.440
Reserves & Surplus	26890.146	40836.329	51009.412
Net worth	28034.509	41983.769	52156.852
Long-term borrowings	1016.875	1057.117	156.111
Short term borrowings	4631.483	3850.283	4100.807
Current Maturities of Long term debt	543.726	26.400	40.767
Total borrowings	6192.084	4933.800	4297.685
Debt/Equity ratio	0.221	0.118	0.082

YEAR-ON-YEAR GROWTH

Year on Year Growth	31.03.2014	31.03.2015	31.03.2016
	(INR In Million)	(INR In Million)	(INR In Million)
Sales	40957.989	43867.844	56154.951
		7.104	28.009

NET PROFIT MARGIN

Net Profit Margin	31.03.2014	31.03.2015	31.03.2016
	(INR In Million)	(INR In Million)	(INR In Million)
Sales	40957.989	43867.844	56154.951
Profit / (Loss)	6072.523	5626.176	10725.495
	14.83%	12.83%	19.10%

ABRIDGED BALANCE SHEET (CONSOLIDATED)

SOURCES OF FUNDS	31.03.2016	31.03.2015
I.              EQUITY AND LIABILITIES
(1)Shareholders' Funds
(a) Share Capital	1147.440	1147.440
(b) Reserves & Surplus	43664.915	35435.229
(c) Money received against share warrants	0.000	0.000
(2) Share Application money pending allotment	0.000	0.000
Total Shareholders’ Funds	44812.355	36582.669
(3) Non-Current Liabilities
(a) long-term borrowings	1003.989	1107.853
(b) Deferred tax liabilities (Net)	1564.964	1288.704
(c) Other long term liabilities	226.922	233.982
(d) long-term provisions	752.035	547.523
Total Non-current Liabilities	3547.910	3178.062
(4) Current Liabilities
(a) Short term borrowings	5149.232	6106.199
(b) Trade payables	11871.331	8512.302
(c) Other current liabilities	1012.295	1119.628
(d) Short-term provisions	5.614	418.711
Total Current Liabilities	18038.472	16156.840
TOTAL	66398.737	55917.571
II.          ASSETS
(1) Non-current assets
(a) Fixed Assets
(i) Tangible assets	10869.912	9759.869
(ii) Intangible Assets	10684.985	11525.863
(iii) Capital work-in-progress	2853.170	1147.332
(iv) Intangible assets under development	1880.318	3126.599
(b) Non-current Investments	33.168	31.296
(c) Deferred tax assets (net)	1051.417	1005.577
(d) Long-term Loan and Advances	1551.885	1196.981
(e) Other Non-current assets	662.584	513.754
Total Non-Current Assets	29587.439	28307.271
(2) Current assets
(a) Current investments	0.000	0.000
(b) Inventories	16274.505	11299.175
(c) Trade receivables	14191.907	11671.035
(d) Cash and cash equivalents	864.521	744.820
(e) Short-term loans and advances	5480.365	3895.270
(f) Other current assets	0.000	0.000
Total Current Assets	36811.298	27610.300
TOTAL	66398.737	55917.571

PROFIT & LOSS ACCOUNT (CONSOLIDATED)

	PARTICULARS	31.03.2016	31.03.2015
	SALES
	Income	65691.516	51558.273
	Other Income	133.039	500.250
	TOTAL	65824.555	52058.523
Less	EXPENSES
	Cost of Materials Consumed	17219.106	14897.043
	Purchases of Stock-in-Trade	7157.046	5372.006
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(2733.996)	(807.754)
	Employees benefits expense	8348.389	6621.294
	CSR Expenditure	1.248	1.751
	Exceptional Item	4.672	66.052
	Other expenses	21101.703	16033.687
	TOTAL	51098.168	42184.079
Less	PROFIT/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION	14726.387	9874.444
Less	FINANCIAL EXPENSES	209.906	195.170
	PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION	14516.481	9679.274
Less/ Add	DEPRECIATION/ AMORTISATION	2704.414	2486.501
	PROFIT/ (LOSS) BEFORE TAX	11812.067	7192.773
Less	TAX	2987.119	1622.705
	PROFIT/ (LOSS) AFTER TAX	8824.948	5570.068
	Earnings / (Loss) Per Share (INR)	76.91	48.67
	Diluted	76.91	48.54

LOCAL AGENCY FURTHER INFORMATION

Sr. No.	Check list by info agents	Available in Report (Yes/No)
1	Year of establishment	Yes
2	Constitution of the entity -Incorporation details	Yes
3	Locality of the entity	Yes
4	Premises details	No
5	Buyer visit details	--
6	Contact numbers	Yes
7	Name of the person contacted	Yes
8	Designation of contact person	Yes
9	Promoter’s background	Yes
10	Date of Birth of Proprietor / Partners / Directors	Yes
11	Pan Card No. of Proprietor / Partners	Yes
12	Voter Id Card No. of Proprietor / Partners	No
13	Type of business	Yes
14	Line of Business	Yes
15	Export/import details (if applicable)	Yes
16	No. of employees	Yes
17	Details of sister concerns	Yes
18	Major suppliers	No
19	Major customers	No
20	Banking Details	Yes
21	Banking facility details	Yes
22	Conduct of the banking account	--
23	Financials, if provided	Yes
24	Capital in the business	Yes
25	Last accounts filed at ROC, if applicable	No
26	Turnover of firm for last four years	Yes
27	Reasons for variation <> 20%	--
28	Estimation for coming financial year	No
29	Profitability for last four years	Yes
30	Major shareholders, if available	Yes
31	External Agency Rating, if available	Yes
32	Litigations that the firm/promoter involved in	Yes
33	Market information	--
34	Payments terms	Yes
35	Negative Reporting by Auditors in the Annual Report	No

NOTE:

The Registered Office Address has been shifted from 2^nd Floor, Chinubhai Centre, Ashram Road, Ahmedabad - 380009, Gujarat, India to the present address.

REVIEW OF BUSINESS OPERATIONS AND FUTURE PROSPECTS (As on 31.03.2016)

During the year, the Company’s standalone Revenue from operations (Net) stood at INR 56154.950 Million as compared to INR 43867.844 Million for the previous year, representing an increase of 28%. Profit before Tax (PBT) stood at INR 13491.032 Million for the year as compared to INR 7056.585 Million for the previous year, representing an increase of 91%; Net Profit stood at INR 10725.495 Million as compared to INR 5626.176 Million for the previous year, representing an increase of 91%.

UNSECURED LOAN

Particular	31.03.2016 (INR in Million)	31.03.2015 (INR in Million)
Long-term Borrowings
Other loans and advances	18.037	929.317
Short-term borrowings
Term loans	669.211	534.655
Other loans and advances	0.000	334.637
Total	687.248	1798.609

INDEX OF CHARGE:

SNO	SRN	CHARGE ID	CHARGE HOLDER NAME	DATE OF CREATION	DATE OF MODIFICATION	DATE OF SATISFACTION	AMOUNT	ADDRESS
1	G54698956	100125104	STANDARD CHARTERED BANK	04/09/2017	-	-	1846170150.0	MARINA BAY FINANCIAL CENTRE TOWER 1, LEVEL 23, 8 MARINA BOULEVARD NANA 018981 SG
2	G33228222	100071690	AXIS TRUSTEE SERVICES LIMITED	28/12/2016	-	-	32182903510.29	AXIS HOUSE, BOMBAY DYEING MILLS COMPOUND, PANDHURANG BUDHKAR MARG, WORLI, MUMBAI – 400025, MAHARASHTRA, INDIA
3	G48611784	100072051	AXIS TRUSTEE SERVICES LIMITED	28/12/2016	14/07/2017	-	18458674000.0	AXIS HOUSE, BOMBAY DYEING MILLS COMPOUND, PANDHURANG BUDHKAR MARG, WORLI, MUMBAI – 400025, MAHARASHTRA, INDIA
4	C18867440	90103163	STATE BANK OF INDIA	25/06/1999	21/08/2014	-	5500000000.0	COMMERCIAL BRANCH, PARAM, SIDDHI COMPLEX, ELLISBRIDGE, AHMEDABAD- 380006, GUJARAT, INDIA
5	Y10197374	90107682	DENA BANK	01/05/1998	-	-	45000000.0	ASHRAM ROAD BRANCH, ASHRAM ROAD, AHMEDABAD – 393009, GUJARAT, INDIA
6	G36605764	10373035	BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL	30/08/2012	14/02/2014	22/02/2017	181120000.0	A-254, 3RD FLOOR, VEERA TOWER, BHISHAM PITAMAH MARG, DEFENCE COLONY, NEW DELHI – 110024, INDIA
7	G22707319	100019286	CITI BANK N.A.	21/03/2016	07/04/2016	15/11/2016	1150000000.0	PLOT NO. C-61, BANDRA KURLA COMPLEX, G-BLOCK, BANDRA (EAST), MUMBAI – 400051, MAHARASHTRA, INDIA
8	C80416654	10443209	IDBI TRUSTEESHIP SERVICES LIMITED	14/06/2013	-	01/03/2016	900000000.0	ASIAN BLDG., GROUND FLOOR, 17, R. KAMANI MARG, BALLARD ESTATE, MUMBAI – 400001, MAHARASHTRA, INDIA
9	C40621856	10242942	CITIBANK N. A.	10/08/2010	31/03/2011	07/01/2015	500000000.0	301, 3RD FLOOR, REMBRANT BUILDING, OPP. ASSOCIATE PETROL PUMP, C.G. ROAD, AHMEDABAD – 380006, GUJARAT, INDIA
10	C40616278	10256338	CITI BANK N.A.	27/10/2010	24/02/2014	07/01/2015	500000000.0	301, 3RD FLOOR, REMBRANT BUILDING, OPP. ASSOCIATE PETROL PUMP, C.G. ROAD, AHMEDABAD – 380006, GUJARAT, INDIA

CONTINGENT LIABILITIES:

(INR in million)

PARTICULARS	31.03.2016	31.03.2015
Estimated amount of contracts remaining to be executed on capital account and not provided for	979.490	620.437
Other commitments	15.317	437.863

FIXED ASSETS

· Land

· Plant and equipment

· Furniture and fixtures

· Vehicles

· Computer equipments

PRESS RELEASES / NEWS

INTAS PHARMACEUTICALS COMPLETES DEAL TO ACQUIRE ACTAVIS UK AND IRELAND GENERICS BUSINESSES FROM TEVA

January 10, 2017

Intas Pharmaceuticals Limited ('Intas'), through its wholly-owned subsidiary Accord Healthcare Limited ('Accord'), announced it has completed the deal to acquire Actavis UK Limited and Actavis Ireland Limited ('Actavis UK and Ireland') from Teva Pharmaceutical Industries Limited ('Teva'), for an enterprise value of £603 million payable in cash. The transaction is part of the European Commission's anti-trust divestiture requirements arising from Teva's acquisition of Allergan's generics business.

Following the completion of the acquisition, Accord strengthens its footprint in the UK and Ireland retail market to become a leading player in the industry at European level, while Intas becomes a top 20 generic player globally. The combination with Actavis UK Limited and Actavis Ireland gives Accord an exciting opportunity to build on its already strong position in the market, providing the Company with increased access to UK and Irish retail and hospital markets. The combination of these two high performing businesses, expands Accord's UK manufacturing presence with the addition of the GMP Barnstaple site owned by Actavis, resulting in a combined regional base revenue of more than half a billion euros per year, and a workforce of more than 1000 employees.

"The completion of this acquisition captures a great opportunity for growth and demonstrates Intas' commitment to greater European expansion," says Mr Binish Chudgar, Vice Chairman and Managing Director of Intas. "The joining of these two companies means we can continue our successful European operating path, which started more than a decade ago. We are a leading generics player in the UK market, with a clear plan for continued growth and development of the Barnstaple site and the Actavis team. Through our subsidiary, Accord Healthcare, we are welcoming the Actavis team into the Intas family and will ensure a smooth integration of the two businesses," Chudgar added.

This acquisition further demonstrates Accord's commitment to UK manufacturing, adding to the recent significant investment to reinstate a facility in Newcastle. The Barnstaple plant will become one of Accord's four UK sites, ensuring the company has one of the most extensive local supply chains to service pharmacies, clinicians, hospitals and wholesalers across UK and Ireland, and into Europe. 

About Intas Pharmaceuticals Limited 

Intas is among the top-10 Indian pharmaceutical companies and the largest privately-held pharmaceutical company in India, with annual turnover in excess of US$ 1 billion, of which 60% comes from international operations. 

The group has an extensive geographic footprint with presence in 70 countries worldwide and more than 80% of export revenue coming from US, UK and EU. 

Intas operates over 10 manufacturing facilities worldwide. These facilities have regulatory approvals from multiple global agencies and enjoy an excellent reputation for quality and compliance. The group has capabilities to produce a wide variety of dosage forms including solid orals, liquids, lyophilized sterile preparations, creams, drops and injectables.

Intas employs 12,000 people globally with over 400 located in Europe. The company employs over 800 scientists; spends approximately 6% of sales on R&D per annum and has been granted 27 international patents.

In addition to generics formulation, R&D is focused on value-added products such as biosimilars, value-added and improved generics using novel drug delivery systems (NDDS) and innovative active pharmaceutical ingredients (API).

Intas has the largest commercialised portfolio of biosimilars in India and is the first Indian pharmaceutical company to launch a biosimilar in the EU.

Intas is privately held, based in Ahmedabad India, and backed by two leading financial investors, Temasek and ChrysCapital

About Accord Healthcare Limited 

Accord is a fully-owned subsidiary of Intas, managing its European activities with presence in over 30 European markets with headquarters in London. 

Accord operates in both primary and secondary care segments with a large European portfolio of more than 6,000 products approvals across 220 molecules. It has a strong product pipeline with 43 molecules under registration and 121 under development.

Accord has been established for more than 10 years in the UK and supplies over 80m packs of medicines per year. The company holds contracts with, and supplies to, all major UK wholesalers, NHS hospitals and The Department of Health. Accord's product portfolio is increasingly focused on complex products with higher technological and clinical requirements. For example, Accord Healthcare launched their first biosimilar, Accofil®, in January 2015, providing an affordable alternative for patients treated with filgrastim. This launch represented the first European biosimilar product developed and produced by an Indian based manufacturer.

Accord already operates an EU GMP manufacturing site in Haverhill, UK and an EU test and release laboratory in London

Accord, recently received the prestigious 'Company of the Year 2016' and 'Company of the Year EMEA 2016' Generics Bulletin Awards.

About Actavis UK and Ireland 

Actavis UK has grown rapidly to become a leading supplier of generic pharmaceuticals in the UK. This success is built upon a strong 175-year UK manufacturing heritage, with over 10% of total UK generic medicines manufactured at the Barnstaple manufacturing facility. Actavis UK supports 85% of UK pharmacists' category M dispensing needs; supporting patients to receive the medicines they need when they need them.

Actavis first entered the Irish market in 2008 with just 15 products and a commitment to provide Irish retail and hospital pharmacists with long-term sustainable value across a broad product portfolio and outstanding customer service. This commitment, based on a partnership approach with pharmacists, has helped Actavis to grow to be a leading generic supplier inIreland with a portfolio of over 100 products. 

CMT REPORT (Corruption, Money Laundering & Terrorism]

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

1] INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

2] Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

3] Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

4] Record on Financial Crime :

Charges or conviction registered against subject: None

5] Records on Violation of Anti-Corruption Laws :

Charges or investigation registered against subject: None

6] Records on Int’l Anti-Money Laundering Laws/Standards :

Charges or investigation registered against subject: None

7] Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

8] Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

9] Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

10] Press Report :

No press reports / filings exists on the subject.

CORPORATE GOVERNANCE

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

CONTRAVENTION

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

FOREIGN EXCHANGE RATES

Currency	Unit	INR
US Dollar	1	INR 64.99
UK Pound	1	INR 90.83
Euro	1	INR 80.58

INFORMATION DETAILS

Information Gathered by :	KAM
Analysis Done by :	PRI
Report Prepared by :	KJL

SCORE FACTORS

DEMERIT POINTS
--BANK CHARGES	YES/NO	YES
--LITIGATION	YES/NO	NO
--OTHER ADVERSE INFORMATION	YES/NO	NO
MERIT POINTS
--SOLE DISTRIBUTORSHIP	YES/NO	NO
--EXPORT ACTIVITIES	YES/NO	YES
--AFFILIATION	YES/NO	YES
--LISTED	YES/NO	NO
--OTHER MERIT FACTORS	YES/NO	YES

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

· Financial condition covering various ratios

· Company background and operations size

· Promoters / Management background

· Payment record

· Litigation against the subject

· Industry scenario / competitor analysis

· Supplier / Customer / Banker review (wherever available)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.